Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,605.32
    -1,623.32 (-3.23%)
     

  • CMC Crypto 200

    1,265.12
    -92.88 (-6.84%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

Factory snag hits GSK supply, causing Danish anaesthetic shortage

Reuters - UK Focus

LONDON, June 17 (Reuters) - Manufacturing problems at a factory in Italy have disrupted production of some GlaxoSmithKline (Other OTC: GLAXF - news) medicines, leading to shortages of a commonly used opioid anaesthetic in Denmark.

The British drugmaker said on Friday it had temporarily suspended manufacturing at its Parma site, which makes sterile products, to investigate environmental monitoring, adding this was unrelated to risks from any medicines.

The factory has now recommenced manufacturing. However, a spokeswoman said a small number of countries had experienced shortages of certain products since April.

In Denmark, doctors said they were running out of the anaesthetic Ultiva, which is a preferred product because patients wake up quickly after surgery. Recovery typically occurs within five to 10 minutes.

The Parma factory also makes GSK's new injectable drug Nucala for severe asthma and Benlysta for lupus, but the spokeswoman said these medicines were not in short supply because there were plentiful stocks. (Reporting by Ben Hirschler; Editing by Alexander Smith)